Web Calculator Estimates Survival of Bowel Cancer Patients
|
By LabMedica International staff writers Posted on 28 Jun 2017 |
For many cancer patients, their diagnosis is soon followed by thoughts of trying to estimate how much time they have left and whether certain treatments could prolong their life. The new online prognostic tool could help manage expectations and make more informed decisions about treatment options.
The calculator was developed by researchers at the University of Nottingham (UN; Nottingham, UK) and medical software company ClinRisk (UK) using the QResearch database, which gathers patient data from approximately 1500 general practices across England through the clinical IT computer systems of EMIS Health. QResearch is a large consolidated database of anonymous health records, developed by a not-for-profit partnership between the UN and EMIS.
“We are grateful for the continued commitment of practices using our systems and their patients who are helping to improving healthcare through data analytics,” said Shaun O’Hanlon, medical director at EMIS Health, “While having the best information is always important, it is how it is delivered and used that is key.”
Accuracy testing showed that the calculator can predict absolute survival rates. It also allows patients to update their mortality risk based on how long they have survived following a diagnosis of cancer.
“Current methods of estimating survival tend to be unreliable and sometimes patients can be given a fairly misleading and unnecessarily gloomy prognosis based only on the grade and stage of their cancer, only to find that in reality they live much longer than these crude predictions,” said Prof. Hippisley-Cox, “This new calculator, which doctors and patients can access, will offer a far more realistic estimate. We understand that not everyone will want to do this, of course, but some patients are very keen on this approach so it’s an individual choice.”
Current methods of predicting survival are based on simple averages based on age or the grade and stage of the cancer in the wider population. To deliver a far more personalized prognosis, the new tool takes into account additional risk factors, including the patient’s smoking history, body mass index, family history, other illnesses and treatments (e.g. aspirin or statins), as well as other information (e.g. whether they have had surgery or treatments such as chemotherapy for the cancer).
The team used information from more than 44,000 patients from 947 practices to develop separate equations for men and women aged between 15-99 years when diagnosed with bowel cancer. They then tested the equations by using them retrospectively to predict the outcome at 1, 5, and 10 years after diagnosis for 15,214 bowel cancer patients from 305 different GP practices, and for 437,821 colorectal cancer patients from the national cancer registry.
The results indicated that they had devised strong models for prediction of cancer survival outcomes. They were also able to provide conditional survival estimates that showed how mortality risks change over time, particularly important among patients where the initial prognosis was poor due to late-stage disease.
For example, a 38-year-old woman with stage 4 advanced bowel cancer might the calculator and see that her chance of surviving for 5 years without any treatment would be predicted to be only 6%; with surgery it would increase to 23%, and with both treatments it would be 45%. This compares with the published chance of 5-year survival of 66% based solely on her age, or the 8% chance based solely on her cancer stage. If she has both treatments and survives for 1 year following diagnosis, her predicted 5-year conditional survival would increase to 57%.
The study, by Hippisley-Cox J and Coupland C, was published June 15, 2017, in the British Medical Journal (BMJ).
Related Links:
University of Nottingham
ClinRisk
The calculator was developed by researchers at the University of Nottingham (UN; Nottingham, UK) and medical software company ClinRisk (UK) using the QResearch database, which gathers patient data from approximately 1500 general practices across England through the clinical IT computer systems of EMIS Health. QResearch is a large consolidated database of anonymous health records, developed by a not-for-profit partnership between the UN and EMIS.
“We are grateful for the continued commitment of practices using our systems and their patients who are helping to improving healthcare through data analytics,” said Shaun O’Hanlon, medical director at EMIS Health, “While having the best information is always important, it is how it is delivered and used that is key.”
Accuracy testing showed that the calculator can predict absolute survival rates. It also allows patients to update their mortality risk based on how long they have survived following a diagnosis of cancer.
“Current methods of estimating survival tend to be unreliable and sometimes patients can be given a fairly misleading and unnecessarily gloomy prognosis based only on the grade and stage of their cancer, only to find that in reality they live much longer than these crude predictions,” said Prof. Hippisley-Cox, “This new calculator, which doctors and patients can access, will offer a far more realistic estimate. We understand that not everyone will want to do this, of course, but some patients are very keen on this approach so it’s an individual choice.”
Current methods of predicting survival are based on simple averages based on age or the grade and stage of the cancer in the wider population. To deliver a far more personalized prognosis, the new tool takes into account additional risk factors, including the patient’s smoking history, body mass index, family history, other illnesses and treatments (e.g. aspirin or statins), as well as other information (e.g. whether they have had surgery or treatments such as chemotherapy for the cancer).
The team used information from more than 44,000 patients from 947 practices to develop separate equations for men and women aged between 15-99 years when diagnosed with bowel cancer. They then tested the equations by using them retrospectively to predict the outcome at 1, 5, and 10 years after diagnosis for 15,214 bowel cancer patients from 305 different GP practices, and for 437,821 colorectal cancer patients from the national cancer registry.
The results indicated that they had devised strong models for prediction of cancer survival outcomes. They were also able to provide conditional survival estimates that showed how mortality risks change over time, particularly important among patients where the initial prognosis was poor due to late-stage disease.
For example, a 38-year-old woman with stage 4 advanced bowel cancer might the calculator and see that her chance of surviving for 5 years without any treatment would be predicted to be only 6%; with surgery it would increase to 23%, and with both treatments it would be 45%. This compares with the published chance of 5-year survival of 66% based solely on her age, or the 8% chance based solely on her cancer stage. If she has both treatments and survives for 1 year following diagnosis, her predicted 5-year conditional survival would increase to 57%.
The study, by Hippisley-Cox J and Coupland C, was published June 15, 2017, in the British Medical Journal (BMJ).
Related Links:
University of Nottingham
ClinRisk
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







